Oxidative phosphorylation

MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights

Retrieved on: 
Giovedì, Maggio 9, 2024
Biotechnology, Pharmaceutical, Health, Oncology, CDK9, Investment, Venetoclax, Research, MEI, Trial of the century, Bevacizumab, AML, Cohort, Oxidative phosphorylation, Wind, Disease, Week, IDH, Patient, Toxicity, Acute myeloid leukemia, FLT3, Clinical trial, Calendar, Pharmaceutical industry

“Over the past several months, MEI has received encouraging clinical data for voruciclib and ME-344 supporting the further development of these programs,” said David Urso, president and chief executive officer of MEI Pharma.

Key Points: 
  • “Over the past several months, MEI has received encouraging clinical data for voruciclib and ME-344 supporting the further development of these programs,” said David Urso, president and chief executive officer of MEI Pharma.
  • As of March 31, 2024, MEI had $56.6 million in cash, cash equivalents, and short-term investments with no outstanding debt.
  • Research and development expenses decreased by $9.9 million to $5.2 million for the quarter ended March 31, 2024, compared to $15.1 million for the quarter ended March 31, 2023.
  • MEI recognized no revenue for the quarter ended March 31, 2024, compared to $5.9 million for the quarter ended March 31, 2023.

MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights

Retrieved on: 
Martedì, Febbraio 13, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Cohort, Oxidative phosphorylation, Hematology, Investment, Calendar, Exposition, Bevacizumab, Safety, Society, Lymphoid leukemia, OXPHOS, Patient, Acute myeloid leukemia, CDK9, MEI, Colorectal cancer, Wind, Pharmaceutical industry

As of December 31, 2023, MEI had $59.5 million in cash, cash equivalents, and short-term investments with no outstanding debt.

Key Points: 
  • As of December 31, 2023, MEI had $59.5 million in cash, cash equivalents, and short-term investments with no outstanding debt.
  • Research and development expenses decreased by $11.4 million to $3.9 million for the quarter ended December 31, 2023, compared to $15.3 million for the quarter ended December 31, 2022.
  • General and administrative expenses decreased by $0.5 million to $8.0 million for the quarter ended December 31, 2023, compared to $8.5 million for the quarter ended December 31, 2022.
  • MEI recognized no revenue for the quarter ended December 31, 2023, compared to $32.7 million for the quarter ended December 31, 2022.

Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024

Retrieved on: 
Lunedì, Gennaio 22, 2024
Brain, Type 2, LMD, Legislation, Incidence, C-peptide, Cancer, SNY, Panobinostat, GBM, Letter, Trial of the century, Neoplasm, CFO, Diffusion, Cell proliferation, Central nervous system, Apoptosis, Type 1 diabetes, Patent, Breast, Metabolism, Diffuse intrinsic pontine glioma, Type 2 diabetes, Survival, DIPG, MGMT, Patient, Toxicology, Glioblastoma, Tolimidone, Pfizer, Insulin, OXPHOS, Plasma, Oxidative phosphorylation, FDA, Progression-free survival, Convection, Columbia University, Type 1, Cerebrospinal fluid, DMG, Pharmaceutical industry

In December 2023, we completed an in-licensing of a new, potentially disease modifying, orally delivered clinical stage molecule for Type I diabetes, an unmet medical disease.

Key Points: 
  • In December 2023, we completed an in-licensing of a new, potentially disease modifying, orally delivered clinical stage molecule for Type I diabetes, an unmet medical disease.
  • Tolimidone is an activator of lyn kinase which has been shown to play a significant role in cell proliferation, differentiation, apoptosis, migration and metabolism.
  • We expect to report data from the in vivo LMD efficacy model by the end of the first quarter of 2024.
  • Certain statements in this shareholder letter may constitute “forward-looking statements” within the meaning of legislation in the United Kingdom and/or United States.

Anavex Announces First Entire Clinical Gene Pathway Data of ANAVEX®2-73 from AVATAR Study in Patients with Rett Syndrome

Retrieved on: 
Mercoledì, Dicembre 20, 2023
RNA, DSM-IV codes, RNA-Seq, AVATAR, Rett syndrome, Oxidative phosphorylation, Sequence, DNA, Gene expression, Neurodevelopmental disorder, CNS, Gene, Biomarker, Central nervous system, Patient, WES, Data collection, Therapy, Pharmaceutical industry

A whole genome and exome analysis comparing drug and placebo in patients with Rett syndrome was performed.

Key Points: 
  • A whole genome and exome analysis comparing drug and placebo in patients with Rett syndrome was performed.
  • AVATAR study was a randomized, placebo-controlled clinical trial in 33 patients with Rett syndrome which included prespecified biomarkers of response as well as Whole Exome Sequencing (WES) DNA data and full RNA exome expression (RNA-seq) data collection.
  • ANAVEX®2-73 transcriptomics analysis (RNAseq) identified gene networks that are differentially expressed in Rett syndrome patients treated with ANAVEX®2-73 compared to placebo.
  • Patient samples that were analyzed contained on average over 20 million unique reads in both placebo and ANAVEX®2-73 treated patients.

Interim results for the six months ended 30 June 2023

Retrieved on: 
Venerdì, Settembre 29, 2023
Oxidative phosphorylation, AIM, Brain, Medication, Data monitoring committee, Decompression (diving), Research, Fine chemical, Pharmaceutical industry, Cancer

Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain, announces its unaudited interim results for the six months ended 30 June 2023 which will also be made available on the Company’s website at www.biodexapharma.com .

Key Points: 
  • Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain, announces its unaudited interim results for the six months ended 30 June 2023 which will also be made available on the Company’s website at www.biodexapharma.com .
  • The Company announced the following in the six months ended 30 June 2023:
    Approval by the Data Safety Monitoring Board to escalate the dose of MTX110 in recurrent glioblastoma (rGBM) to 90µM, the expected optimal therapeutic dose.
  • Closing of a private placement in the US to raise $6.0m before expenses.
  • The Company’s cash balance at 30 June 2023 was £5.23m.

Journal of Cellular and Molecular Medicine Publishes Preclinical Data of Panavance’s GP-2250 to treat Pancreatic Cancer

Retrieved on: 
Martedì, Settembre 12, 2023
Oxidative phosphorylation, Pancreatic cancer, NF, University, Cell death, GAPDH, Glomus tumor, ATP, Enzyme, Agonal respiration, Quality of life, Cancer, Research, Ruhr University Bochum, Molecular medicine, University of Duisburg-Essen, Patient, Manuscript, Apoptosis, Organ (biology), Journal of Cellular and Molecular Medicine, ST, Factorization of polynomials, Pharmaceutical industry, Panaveli

BERWYN, PA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology therapeutic intended to improve the outcomes and quality of life for patients, today announced publication of positive data in the peer-reviewed Journal of Cellular and Molecular Medicine in a manuscript titled, “GP-2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP-Kinase and impairs the NF-kB pathway in pancreatic cancer cells1.” The publication by Majchrzak-Stiller, et al. (2023) details the multiple sites of action of GP-2250 in the disruption of energy production of cancer cells and the downregulation of tumor promoting transcription factors.

Key Points: 
  • GP-2250 is a highly selective yet broadly active cancer therapeutic with a unique mechanism of action that suppresses cancer by disrupting its energy metabolism, leading to cancer cell death through several validated mechanisms.
  • GP-2250 is currently being studied in a Phase 1 clinical trial for pancreatic cancer.
  • Results of the preclinical study showed that at the lowest dose of GP-2250 tested (250 μM), a significant decrease in ATP was apparent at 6 hours in both pancreatic cancer cell lines.
  • We are pleased with the results GP-2250 demonstrated, and the metabolic and transcriptional findings provide molecular targets for GP-2250.

Global Feed Eubiotics Market Report 2023: Sector is Expected to Reach $7.31 Billion by 2030 at a CAGR of 6.1% - ResearchAndMarkets.com

Retrieved on: 
Lunedì, Luglio 17, 2023
Agriculture, Natural Resources, Oxidative phosphorylation, Poultry, Aquaculture, Nutrient, Livestock, MEA, Research, Element, USD, Nutritional science, Immunity, Animal, Metabolism, Application, Plant growth analysis, Form, Health, Pig, Meat, Probiotic, Animal feed

During the analysis period, each of these elements will fuel demand and advance the global feed eubiotics market.

Key Points: 
  • During the analysis period, each of these elements will fuel demand and advance the global feed eubiotics market.
  • The global feed eubiotics market is segmented based on type, application, and region.
  • By end use, the market is segmented into cattle feed, poultry feed, swine feed, aquatic feed, and others.
  • Based on region, the global Feed Eubiotics market is segmented into North America, Europe, Asia-Pacific, South America, and MEA.

Reneo Pharmaceuticals to Present Preclinical Mavodelpar (REN001) Data at the Society for Inherited Metabolic Disorders Annual Meeting 2023

Retrieved on: 
Giovedì, Marzo 9, 2023
Gene, Annual general meeting, Mitochondrial disease, Mouse, Skeleton, DNA, Patient, STRIDE, SIMD, A-DNA, Society, PMM, Oxidative phosphorylation, Pharmaceutical industry, Publication

IRVINE, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company will present a preclinical poster at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting, being held in Salt Lake City, Utah, Mar.

Key Points: 
  • IRVINE, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company will present a preclinical poster at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting, being held in Salt Lake City, Utah, Mar.
  • Further, mavodelpar activation of PPARδ in mice was found to increase expression of genes involved in fatty acid metabolism, oxidative phosphorylation, and mitochondrial biogenesis.
  • Mavodelpar is currently being evaluated in a pivotal randomized controlled clinical trial, REN001-201 (STRIDE; NCT04535609) in adult patients with primary mitochondrial myopathies (PMM) with confirmed mitochondrial DNA (mtDNA) defects.
  • The poster presentation will be available on the Presentations and Publications page of the Reneo Pharmaceuticals website following the event.

ImmunoMet Therapeutics Announces First Patient Dosed in a Phase 1b Trial of IM156 in Pancreatic Cancer

Retrieved on: 
Giovedì, Novembre 17, 2022
Research, Professional Services, Pharmaceutical, Oncology, Venture Capital, Technology, Clinical Trials, Science, Nanotechnology, Biotechnology, FDA, Health, PFS, Biguanide, Clinical trial, Series, MD Anderson Cancer Center, ORR, PC1, Phosphorylation, Protein, Therapy, OXPHOS, Cancer, University, Neoplasm, Disease, Safety, Progression-free survival, Associate professor, Metabolism, Oxidative phosphorylation, RECIST, Division, Mortality, Pancreatic cancer, Oncology, MD, Patient, Pharmaceutical industry

ImmunoMet Therapeutics, Inc., a clinical stage biotechnology company targeting metabolism to develop novel anti-cancer and anti-fibrotic therapies, today announces that the first patient has been dosed in the single-arm Phase 1b trial of IM156 in combination with gemcitabine and nab-paclitaxel as frontline therapy in patients with advanced pancreatic cancer.

Key Points: 
  • ImmunoMet Therapeutics, Inc., a clinical stage biotechnology company targeting metabolism to develop novel anti-cancer and anti-fibrotic therapies, today announces that the first patient has been dosed in the single-arm Phase 1b trial of IM156 in combination with gemcitabine and nab-paclitaxel as frontline therapy in patients with advanced pancreatic cancer.
  • This clinical trial evaluates the potential of IM156 in combination with gemcitabine and nab-paclitaxel to address resistance and improve patient outcomes.
  • The trial includes a dose escalation phase followed by an expansion phase, treating a total of approximately 25 patients with advanced pancreatic cancer.
  • We are hopeful that this potentially best-in-class OxPhos inhibitor can improve outcomes for these patients, said Dean Welsch, CEO of ImmunoMet Therapeutics.

Cell Stress and Mitochondrial Dysfunction Found in Early Alzheimer’s Disease Patients, Findings Published in Science Translational Medicine

Retrieved on: 
Giovedì, Agosto 18, 2022
Research, Mental Health, Neurology, Clinical Trials, Stem Cells, Biotechnology, General Health, Pharmaceutical, Health, Science, Gaia, Multimedia, Biomarker, Magnetic resonance imaging, Receptor (biochemistry), Degenerative disease, United Kingdom, Mitochondrion, AI, Molecular imaging, CRO, Oxidative phosphorylation, LLC, Research, Translation, SV2A, Area studies, Patient, Engineering, PET, EVP, Imperial College London, Neurology, Neurodegeneration, Role, CSO, Protein, AD, MIND, MAPS, Science Translational Medicine, Solution, Publishing, Medicine, Health, Medical imaging, Science, Synapse, Neuroscience

Invicro LLC (Invicro), a global, industry-leading imaging CRO, and a subsidiary of REALM IDx, Inc. , today announced the publication of the paper Widespread cell stress and mitochondrial dysfunction occur in patients with early Alzheimers disease1 in Science Translational Medicine.

Key Points: 
  • Invicro LLC (Invicro), a global, industry-leading imaging CRO, and a subsidiary of REALM IDx, Inc. , today announced the publication of the paper Widespread cell stress and mitochondrial dysfunction occur in patients with early Alzheimers disease1 in Science Translational Medicine.
  • (Graphic: Business Wire)
    The study provides novel in vivo evidence for widespread, clinically relevant cellular stress and bioenergetic abnormalities in patients with early-stage Alzheimers Disease (AD) and highlights the potential value of mitochondrial imaging in longitudinal studies of AD.
  • Science Translational Medicine is the leading weekly online journal publishing translational research at the intersection of science, engineering and medicine.
  • Science Translational Medicine published Widespread cell stress and mitochondrial dysfunction occur in patients with early Alzheimers disease on August 17, 2022.